Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 7/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PRKDC | P78527 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405233 | 0.84 | CDK5 (0.57) | ATRGRM5CDK5CDK5R1ALDH1A1 | |
| SCHEMBL3402767 | 0.84 | ATR (0.48) | ATRGRM5CDK5CDK5R1CCNA2 | |
| SCHEMBL410727 | 0.82 | ATR (0.58) | ATRGRM5MAPTHTTALDH1A1 | |
| SCHEMBL30504276 | 0.82 | GRM5 (0.55) | ATRGRM5CDK5CDK5R1ALDH1A1 | |
| SCHEMBL3374259 | 0.82 | CDK5 (0.43) | ATRCDK5CDK5R1MAPTALDH1A1 | |
| SCHEMBL11786153 | 0.82 | GRM5 (0.55) | ATRGRM5CDK5CDK5R1ALDH1A1 | |
| SCHEMBL12343678 | 0.82 | GRM5 (0.55) | ATRGRM5CDK5CDK5R1MAPT | |
| SCHEMBL560127 | 0.81 | ATR (0.68) | ATRGRM5PRKDCATMNPC1 | |
| SCHEMBL5684569 | 0.81 | ATR (0.63) | ATRCDK5CDK5R1PRKDCATM | |
| SCHEMBL617641 | 0.80 | ATR (0.55) | ATRGRM5PRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8431698-B2 | Bioluminescent endoscopy methods and compounds | BIOLUME INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-102036961-A | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090081129-A1 | Bioluminescent Endoscopy Methods And Compounds | BIOLUME, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-0914318-A1 | PYRAZINES | KINGS COLLEGE LONDON (GB) | 1999-05-12 | — | — | EP | disclosed |
| WO-1997043267-A1 | PYRAZINES | KINGS COLLEGE LONDON (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | ATR 4183/4885GRM5 3387/4885CDK5 4241/4885 |
| US-20090081129-A1 | Bioluminescent Endoscopy Methods And Compounds | SI, MLN, SLC10A2 | ATR 4860/4885GRM5 937/4885CDK5 3609/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | ATR 4183/4885GRM5 3387/4885CDK5 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.